Liquidia Corporation (LQDA) Dividend History

Liquidia Corporation (LQDA) is a biotechnology company focused on the development and commercialization of innovative products using its proprietary PRINT (Particle Replication in Non-wetting Templates) technology. The company's primary areas of interest include treatments in the fields of pulmonary, infectious, and other specialized diseases. Liquidia aims to improve drug delivery and therapeutic outcomes through its advanced particle engineering platform.

419 Davis Drive, Suite 100, Morrisville, NC, 27560
Phone: 919.328.4400
Website: https://www.liquidia.com

Dividend History

Liquidia Corporation currently does not pay dividends

Company News

U.S. FDA Approves Liquidia’s YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

The U.S. FDA has approved Liquidia's YUTREPIA, an inhaled dry-powder formulation of treprostinil, for the treatment of PAH and PH-ILD. The approval is based on the INSPIRE trial, which demonstrated YUTREPIA's safety, tolerability, and efficacy.

GlobeNewswire Inc.

Featured Companies: UTHR
Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics

Liquidia Corporation announced that United Therapeutics filed a complaint alleging infringement of a patent related to inhaled treprostinil. Liquidia stated it has invalidated similar claims in the past and will continue to defend patients' access to its therapy.

GlobeNewswire Inc.

Featured Companies: UTHR
District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia

The U.S. District Court for the District of Columbia dismissed a cross-claim filed by United Therapeutics that sought to challenge Liquidia's amendment to its New Drug Application for YUTREPIA, which added the treatment of pulmonary hypertension associated with interstitial lung disease to the proposed label. Liquidia remains focused on the potential final approval of YUTREPIA following the expiration of regulatory exclusivity.

GlobeNewswire Inc.

Featured Companies: UTHR
Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025

Liquidia Corporation, a biopharmaceutical company, announced that it will report its full year 2024 financial results and provide a corporate update on March 19, 2025. The company is focused on developing innovative therapies for patients with rare cardiopulmonary diseases, including pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

GlobeNewswire Inc.
Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

Atea Pharmaceuticals, a clinical-stage biopharmaceutical company, announced the appointment of Arthur S. Kirsch to its Board of Directors. Kirsch has extensive experience in investment banking and capital markets, as well as knowledge of the healthcare and life sciences industries.

GlobeNewswire Inc.

Featured Companies: AVIR

Dividend data last updated 06/07/2025 03:54:23 UTC